Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01JFM
|
|||
| Former ID |
DIB001402
|
|||
| Drug Name |
AC-170
|
|||
| Synonyms |
88139-91-7; 5-Bromo-2-hydroxymethylpyridine; (5-Bromopyridin-2-yl)methanol; 2-hydroxymethyl-5-bromopyridine; 5-Bromo-2-(hydroxymethyl)pyridine; (5-bromopyrid-2-yl)methanol; 5-Bromo-2-pyridinemethanol; (5-Bromo-pyridin-2-yl)-methanol; 2-PYRIDINEMETHANOL, 5-BROMO-; 5-BROMOPYRIDINE-2-METHANOL; (5-bromo-2-pyridyl)methanol; (5-bromo-2-pyridyl)methan-1-ol; AC-170; (5-Bromo-pyridin-2-yl)methanol (5-Bromo-2-hydroxymethylpyridine); zlchem 391; PubChem7710; PubChem12387; ACMC-209qrb; AC1NP90H; 5-bromo-2-pyridine methanol; KSC494K9D
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allergic conjunctivitis [ICD-11: 9A60.02; ICD-10: H10.1] | Phase 3 | [1] | |
| Company |
Aciex Therapeutics Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H6BrNO
|
|||
| Canonical SMILES |
C1=CC(=NC=C1Br)CO
|
|||
| InChI |
1S/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2
|
|||
| InChIKey |
RUCZFWMEACWFER-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 88139-91-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7734748, 8593186, 29203677, 39115928, 74318916, 75371566, 87561522, 87618057, 90271523, 92719515, 93579511, 99225392, 113775484, 118313039, 121360709, 124391777, 125359099, 126582968, 126590168, 126611515, 126620747, 126652955, 126671163, 126723742, 127629489, 129182084, 131391586, 131537930, 135721089, 136024226, 136370606, 136912257, 136984564, 136997320, 137269821, 140337842, 143438216, 143500659, 152244094, 152248436, 160806450, 160979238, 162147678, 162180243, 162298277, 162762909, 163810366, 164195039, 164757961, 170499800
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02132169) A Multi-Center Study Evaluating the Safety of AC-170 0.24%. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of NicOx SA. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.